首页> 外文期刊>Planta medica: Natural products and medicinal plant research >The Integration of Metabolomics and Next-Generation Sequencing Data to Elucidate the Pathways of Natural Product Metabolism in Medicinal Plants
【24h】

The Integration of Metabolomics and Next-Generation Sequencing Data to Elucidate the Pathways of Natural Product Metabolism in Medicinal Plants

机译:代谢组合和下一代测序数据的整合阐明了药用植物中天然产物代谢的途径

获取原文
获取原文并翻译 | 示例
           

摘要

Plants have always been used as medicines since ancient times to treat diseases. The knowledge around the active components of herbal preparations has remained nevertheless fragmentary: the biosynthetic pathways of many secondary metabolites of pharmacological importance have been clarified only in a few species, while the chemodiversity present in many medicinal plants has remained largely unexplored. Despite the advancements of synthetic biology for production of medicinal compounds in heterologous hosts, the native plant species are often the most reliable and economic source for their production. It thus becomes fundamental to investigate the metabolic composition of medicinal plants to characterize their natural metabolic diversity and to define the biosynthetic routes in planta of important compounds to develop strategies to further increase their content. We present here a number of case studies for selected classes of secondary metabolites and we review their health benefits and the historical developments in their structural elucidation and characterization of biosynthetic genes. We cover the cases of benzoisoquinoline and monoterpenoid indole alkaloids, cannabinoids, caffeine, ginsenosides, withanolides, artemisinin, and taxol; we show how the “early” biochemical or the more recent integrative approaches–based on omics-analyses–have helped to elucidate their metabolic pathways and cellular compartmentation. We also summarize how the knowledge generated about their biosynthesis has been used to develop metabolic engineering strategies in heterologous and native hosts. We conclude that following the advent of novel, high-throughput and cost-effective analytical technologies, the secondary metabolism of medicinal plants can now be examined under the lens of systems biology.
机译:自古以来以自古以来治疗疾病的植物一直被用作药物。围绕草药制剂的活性成分的知识仍然是零碎的:许多药理重要性的生物合成途径只在几种物种中澄清,而许多药用植物中存在的化学大学已经大大未探索。尽管在异源宿主中生产药用化合物的合成生物学的进步,但原生植物物种往往是其生产最可靠和最经济的来源。因此,研究药用植物的代谢组成,以表征其天然代谢多样性并在重要化合物的植物中定义生物合成途径,以制定进一步提高其内容的策略的生物合成途径来实现基本的。我们在这里为选定的次级代谢产物提供了许多案例研究,我们审查了他们的健康益处和其结构阐释的历史发展和生物合成基因的表征。我们涵盖了苯并异喹啉和单萜吲哚生物碱,大麻素,咖啡因,人参皂苷,甘蔗糖苷,阿尔胺蛋白和紫杉醇的病例;我们展示了如何基于OMICS分析的“早期”生化或最近的综合方法 - 已经有助于阐明其代谢途径和细胞舱。我们还总结了对其生物合成产生的知识是如何用于开发异源和本土主体中的代谢工程策略。我们得出结论,在新颖的,高通量和经济高效的分析技术的出现之后,现在可以在系统生物学镜片下检查药用植物的二次代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号